170 related articles for article (PubMed ID: 36060015)
1. KIFC1: A Reliable Prognostic Biomarker in Rb-positive Triple-negative Breast Cancer Patients Treated With Doxorubicin in Combination With Abemaciclib.
Fleisher B; Werkman C; Jacobs B; Varkey J; Taha K; Ait-Oudhia S
Cancer Diagn Progn; 2022; 2(5):525-532. PubMed ID: 36060015
[TBL] [Abstract][Full Text] [Related]
2. In vitro to Clinical Translation of Combinatorial Effects of Doxorubicin and Abemaciclib in Rb-Positive Triple Negative Breast Cancer: A Systems-Based Pharmacokinetic/Pharmacodynamic Modeling Approach.
Fleisher B; Lezeau J; Werkman C; Jacobs B; Ait-Oudhia S
Breast Cancer (Dove Med Press); 2021; 13():87-105. PubMed ID: 33628047
[TBL] [Abstract][Full Text] [Related]
3. Combination therapy application of Abemaciclib with Doxorubicin in triple negative breast cancer cell line MDA-MB-231.
Eralp TN; Sevinc A; Mansuroglu B
Cell Mol Biol (Noisy-le-grand); 2024 Feb; 70(2):169-177. PubMed ID: 38430025
[TBL] [Abstract][Full Text] [Related]
4. Combination Treatment with EGFR Inhibitor and Doxorubicin Synergistically Inhibits Proliferation of MCF-7 Cells and MDA-MB-231 Triple-Negative Breast Cancer Cells In Vitro.
Abrahams B; Gerber A; Hiss DC
Int J Mol Sci; 2024 Mar; 25(5):. PubMed ID: 38474312
[TBL] [Abstract][Full Text] [Related]
5. Novel sequential treatment with palbociclib enhances the effect of cisplatin in RB-proficient triple-negative breast cancer.
Huang Y; Wu H; Li X
Cancer Cell Int; 2020; 20():501. PubMed ID: 33061853
[TBL] [Abstract][Full Text] [Related]
6. Combination of palbociclib with enzalutamide shows in vitro activity in RB proficient and androgen receptor positive triple negative breast cancer cells.
Liu CY; Lau KY; Hsu CC; Chen JL; Lee CH; Huang TT; Chen YT; Huang CT; Lin PH; Tseng LM
PLoS One; 2017; 12(12):e0189007. PubMed ID: 29261702
[TBL] [Abstract][Full Text] [Related]
7. ImmunoPET Imaging Identifies the Optimal Timepoint for Combination Therapy in Xenograft Models of Triple-Negative Breast Cancer.
Li Z; Belitzky E; Blaha O; Cavaliere A; Katz SR; Aboian M; Melegari L; Rajabimoghadam K; Kurpiewski S; Zhu X; Marquez-Nostra B
Cancers (Basel); 2023 Mar; 15(5):. PubMed ID: 36900378
[TBL] [Abstract][Full Text] [Related]
8. Resistance to cyclin-dependent kinase (CDK) 4/6 inhibitors confers cross-resistance to other CDK inhibitors but not to chemotherapeutic agents in breast cancer cells.
Ogata R; Kishino E; Saitoh W; Koike Y; Kurebayashi J
Breast Cancer; 2021 Jan; 28(1):206-215. PubMed ID: 32860163
[TBL] [Abstract][Full Text] [Related]
9. Endocan as a prognostic biomarker of triple-negative breast cancer.
Sagara A; Igarashi K; Otsuka M; Kodama A; Yamashita M; Sugiura R; Karasawa T; Arakawa K; Narita M; Kuzumaki N; Narita M; Kato Y
Breast Cancer Res Treat; 2017 Jan; 161(2):269-278. PubMed ID: 27888420
[TBL] [Abstract][Full Text] [Related]
10. Elevated estrogen receptor β expression in triple negative breast cancer cells is associated with sensitivity to doxorubicin by inhibiting the PI3K/AKT/mTOR signaling pathway.
Lei S; Fan P; Wang M; Zhang C; Jiang Y; Huang S; Fang M; He Z; Wu A
Exp Ther Med; 2020 Aug; 20(2):1630-1636. PubMed ID: 32742395
[TBL] [Abstract][Full Text] [Related]
11. A Second-Generation Proteasome Inhibitor and Doxorubicin Modulates IL-6, pSTAT-3 and NF-kB Activity in MDA-MB-231 Breast Cancer Cells.
Vyas D; Lopez-Hisijos N; Shah P; Deshpande KS; Basson MD; Vyas A; Chaturvedi LS
J Nanosci Nanotechnol; 2017 Jan; 17(1):175-85. PubMed ID: 29617099
[TBL] [Abstract][Full Text] [Related]
12. Multi-institutional study of nuclear KIFC1 as a biomarker of poor prognosis in African American women with triple-negative breast cancer.
Ogden A; Garlapati C; Li XB; Turaga RC; Oprea-Ilies G; Wright N; Bhattarai S; Mittal K; Wetherilt CS; Krishnamurti U; Reid MD; Jones M; Gupta M; Osan R; Pattni S; Riaz A; Klimov S; Rao A; Cantuaria G; Rida PC; Aneja R
Sci Rep; 2017 Feb; 7():42289. PubMed ID: 28218233
[TBL] [Abstract][Full Text] [Related]
13. Kinesin Family Member C1 (KIFC1/HSET) Underlies Aggressive Disease in Androgen Receptor-Low and Basal-Like Triple-Negative Breast Cancers.
Jinna N; Yuan YC; Rida P
Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003261
[TBL] [Abstract][Full Text] [Related]
14. Expression and regulatory function of miRNA-182 in triple-negative breast cancer cells through its targeting of profilin 1.
Liu H; Wang Y; Li X; Zhang YJ; Li J; Zheng YQ; Liu M; Song X; Li XR
Tumour Biol; 2013 Jun; 34(3):1713-22. PubMed ID: 23430586
[TBL] [Abstract][Full Text] [Related]
15. Enhancing chemosensitivity of wild-type and drug-resistant MDA-MB-231 triple-negative breast cancer cell line to doxorubicin by silencing of STAT 3, Notch-1, and β-catenin genes.
Alkaraki A; Alshaer W; Wehaibi S; Gharaibeh L; Abuarqoub D; Alqudah DA; Al-Azzawi H; Zureigat H; Souleiman M; Awidi A
Breast Cancer; 2020 Sep; 27(5):989-998. PubMed ID: 32328816
[TBL] [Abstract][Full Text] [Related]
16. HDAC6 inhibition enhances the anti-tumor effect of eribulin through tubulin acetylation in triple-negative breast cancer cells.
Oba T; Ono M; Matoba H; Uehara T; Hasegawa Y; Ito KI
Breast Cancer Res Treat; 2021 Feb; 186(1):37-51. PubMed ID: 33452951
[TBL] [Abstract][Full Text] [Related]
17. Morin Sensitizes MDA-MB-231 Triple-Negative Breast Cancer Cells to Doxorubicin Cytotoxicity by Suppressing FOXM1 and Attenuating EGFR/STAT3 Signaling Pathways.
Maharjan S; Lee MG; Kim SY; Lee KS; Nam KS
Pharmaceuticals (Basel); 2023 Apr; 16(5):. PubMed ID: 37242455
[TBL] [Abstract][Full Text] [Related]
18. Different mechanisms involved in the berberine-induced antiproliferation effects in triple-negative breast cancer cell lines.
Lin YS; Chiu YC; Tsai YH; Tsai YF; Wang JY; Tseng LM; Chiu JH
J Cell Biochem; 2019 Aug; 120(8):13531-13544. PubMed ID: 30957305
[TBL] [Abstract][Full Text] [Related]
19. Combined kinase inhibitors of MEK1/2 and either PI3K or PDGFR are efficacious in intracranial triple-negative breast cancer.
Van Swearingen AED; Sambade MJ; Siegel MB; Sud S; McNeill RS; Bevill SM; Chen X; Bash RE; Mounsey L; Golitz BT; Santos C; Deal A; Parker JS; Rashid N; Miller CR; Johnson GL; Anders CK
Neuro Oncol; 2017 Oct; 19(11):1481-1493. PubMed ID: 28486691
[TBL] [Abstract][Full Text] [Related]
20. Next-generation proteasome inhibitor oprozomib enhances sensitivity to doxorubicin in triple-negative breast cancer cells.
Shi Y; Bieerkehazhi S; Ma H
Int J Clin Exp Pathol; 2018; 11(5):2347-2355. PubMed ID: 31938346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]